Groupama Asset Managment Sells 78,602 Shares of Natera, Inc. (NASDAQ:NTRA)

Groupama Asset Managment reduced its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 58.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 54,998 shares of the medical research company’s stock after selling 78,602 shares during the period. Groupama Asset Managment’s holdings in Natera were worth $8,720,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Blue Trust Inc. boosted its stake in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 97 shares during the last quarter. Versant Capital Management Inc lifted its holdings in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 166 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock valued at $52,000 after purchasing an additional 261 shares in the last quarter. Principal Securities Inc. boosted its position in shares of Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after buying an additional 59 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC grew its holdings in Natera by 1,328.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock worth $57,000 after buying an additional 332 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Buying and Selling

In related news, CFO Michael Burkes Brophy sold 2,562 shares of the business’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $138.41, for a total transaction of $354,606.42. Following the sale, the chief financial officer now directly owns 75,557 shares in the company, valued at approximately $10,457,844.37. The trade was a 3.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Solomon Moshkevich sold 24,861 shares of the firm’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $4,101,319.17. Following the completion of the transaction, the insider now owns 140,684 shares of the company’s stock, valued at approximately $23,208,639.48. This represents a 15.02 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 318,922 shares of company stock valued at $50,619,104. Company insiders own 7.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on NTRA. BTIG Research restated a “buy” rating on shares of Natera in a research note on Friday, February 28th. Piper Sandler raised their price target on shares of Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. Sanford C. Bernstein boosted their price target on shares of Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, January 10th. JPMorgan Chase & Co. increased their price objective on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Finally, Barclays assumed coverage on Natera in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 target price on the stock. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $178.12.

Natera Stock Down 0.5 %

NTRA stock opened at $140.65 on Wednesday. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00. The stock has a fifty day moving average of $158.72 and a 200-day moving average of $151.35. The company has a market capitalization of $19.01 billion, a price-to-earnings ratio of -79.91 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. As a group, equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.